**CURRICULUM VITAE**

Edward Paul Havranek, M.D.

**WORK ADDRESS**

Denver Health Medical Center, 777 Bannock Str., Denver, CO 80204

(303) 602-3852 phone

(303) 602-3900 fax

Ed.Havranek@dhha.org

**EDUCATION**

*University* BS (Chemical Engineering), Cornell University, Ithaca, NY, 1977

*Graduate* MS (Bioengineering) University of Utah, Salt Lake City, UT, 1979

*Medical School* MD, University of Vermont, Burlington, VT, 1983

*Residency* Internal Medicine, University of Colorado HSC, 1983-1986

*Fellowship* Cardiology, University of Wisconsin Hospital, 1986-1989

**HOSPITAL POSITIONS**

*1989-1990* Cardiologist, Metropolitan Cardiology Consultants, Coon Rapids, MN

*1991 -* Staff Cardiologist, Denver Health Medical Center

*2010-2016* Director of Health Services Research, Denver Health

*2015-2016* Interim Director, Department of Medicine, Denver Health

*2016 -* Director, Department of Medicine, Denver Health

**ACADEMIC POSITIONS**

*1991-1997* Assistant Professor of Medicine, University of Colorado School of Medicine

*1997-2004* Associate Professor of Medicine, University of Colorado School of Medicine

*2004-* Professor of Medicine, University of Colorado School of Medicine

|  |  |
| --- | --- |
| *2014*-*2016* | Director, Adult Program - ACCORDS (Adult-Child Consortium for Outcomes Research & Delivery Science), University of Colorado School of Medicine |

**BOARD CERTIFICATION**

*1986* American Board of Internal Medicine

*1989* American Board of Internal Medicine, Cardiovascular Disease

**LICENSURE** Colorado #26367

**PROFESSIONAL ACTIVITIES**

Cardiology consultant, CFMC (Colorado Medicare quality improvement organization), 1996-2005

Technical Review Panel, Centers of Excellence Demonstration Project (Medicare), Health Care Financing Administration, 1997

Clinical Coordinator for National Heart Care (NHC) Project, Centers for Medicare & Medicaid Studies, 1999-2005

Technical Review Panel, Disease Management for Congestive Heart Failure Demonstration Project (Medicare), Health Care Financing Administration 1999

Expert Panel, Medicare Managed Care Quality Indicator Thresholds for Congestive Heart Failure, Health Care Financing Administration, 1999

National Peer Review Committee- Outcomes Research, American Heart Association, 2000

Editorial Board, Journal of Cardiac Failure, 2005-2013

Editorial Board, Journal of the American College of Cardiology, 2004-present

Editorial Board, American Heart Journal, 2005-present

Health Information Technology Advisory Committee, State of Colorado, 2008-2009

Technology Advisory Committee, Colorado Regional Health Information Organization (CORHIO), 2009-2010

National Quality Forum- Steering Committee- Voluntary Consensus Standards for Healthcare Disparities and Cultural Competency, 2011-12

Affiliated Faculty, Center for Global Health, University of Colorado School of Public Health, 2013 - present

NIH Health Services Organization and Delivery Study Section. Member – 2014-2018.

NIH Special Emphasis Review Panels

- Cardiac Translation Research Implementation Program (C-TRIP), July 2009

- Effects of the Social Environment on Health: Measurement, Method, and Mechanisms, June 2011

- Stroke Prevention/Intervention Research Program (SPIRP), July 2012

- Health Services Organization and Delivery - October 2012, February 2013, June 2013

- Nursing-Related Clinical and Interventions Studies (chair) - December 2013

- Fellowships: Epidemiology and Population Sciences – October 2019

- BLOODSAFE: Enhancing availability of safe blood in sub-Saharan Africa – November 2019

- HLB-SIMPLe: Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV - April 2020 (chair)

**EDUCATIONAL ACTIVITIES**

Director, Cardiology Fellowship Training Program, University of Colorado, 1998-2004

Intern Selection Committee, UCSoM Department of Medicine, 2001- 2007

Admissions Committee, University of Colorado School of Medicine, 2007 - 2014

**HOSPITAL ADMINISTRATIVE ACTIVITIES**

Director, Denver Health Medical Center Cardiac Catheterization Laboratory, 1991- 2007

Chair of ad hoc committee developing emergency department-based short stay unit for patients presenting with chest pain, 1992-1994.

Acting Chief of Cardiology, Denver Health Medical Center, 1994-1998

Managed Care Quality Assurance Committee, 1997-2006

Co-Chair, Ambulatory Hypertension Quality Improvement committee, 2007-2009

Ambulatory Care Quality Improvement committee, 2009- 2014

Co-Chair, New Products Review committee, 2001-2014

**PROFESSIONAL ORGANIZATION ACTIVITIES**

Denver Health and Hospitals Medical Staff

* Secretary-Treasurer 1994-1995

American College of Physicians, Fellow

* Health and Public Policy Committee, Colorado Chapter, member 1993-1998; chair 1994-1998
* Governor's Advisory Board, Colorado Chapter, 1993-1997

American College of Cardiology, Fellow

* Heart Failure subcommittee, Database Research and Development committee, 2000-2001
* Advisory Panel, Heart Failure Guidelines Applied in Practice (GAP) project, 2002
* ACC/AHA Task Force on Clinical Data Standards for Heart Failure, 2005-2007, 2013-

Heart Failure Society of America

* Care Standards committee, 2001- 2006 (Chair 2002-2006)

American Heart Association, Fellow

* Database Steering committee, 2006-2010
* Quality of Care/Outcomes Research Annual Scientific Forum Program Committee  
   Co-Vice Chair, 2009  
   Chair, 2010-11
* Committee on Scientific Sessions Program, 2010-11
* International Mentorship Coordinator, Quality of Care & Outcomes Research Council
* Chair, Committee on Social Determinants of Cardiovascular Health, 2014-2015

**AWARDS**

Excellence in Teaching Award, fourth year medical students, May 1993

Outstanding Cardiology Faculty Award, cardiology fellows, 1993-1994

Outstanding Faculty Teaching Award, Denver Health Medical Staff, 2002

Elite Reviewer, Journal of the American College of Cardiology: 2004, 2007

Exceptional Reviewer, Medical Care: 2006, 2008

Outstanding Reviewer, American Heart Journal: 2015

Academic Excellence Award, Denver Health Medical Staff, 2008

Distinguished Academic Achievement Award, University of Vermont Medical Alumni Association, 2013

**CURRENT FUNDING**

*An intervention to increase engagement with hypertension care for American Indian patients*. This project will use a randomized design to test the impact of a values affirmation exercise on adherence with hypertension medications in a group of American Indian patients, comparing results with a group of white patients. The project is part of a Center grant to the University of Colorado School of Public Health (Spero Manson, Center Director). American Heart Association

Principal Investigator, 2.4 calendar-months

2015-2019

$1,042,800

*Using values affirmation to reduce the effects of perceived discrimination on hypertension disparities*. This multicenter study project assesses the effect of a values affirmation exercise on the primary outcome of 6-month change in adherence to antihypertensive therapies, explores possible mechanisms of the intervention effect, and evaluates readiness for dissemination. NIH/NHLBI R01 HL133343-01

Co-Investigator (Stacie Daugherty, PI), 1.2 calendar months

2016-2020

$91,981 (subcontract only)

*IMPlementation to Achieve Clinical Transformation (IMPACT): The Colorado Training Program*. This K12 program will train post-graduate and post-fellowship trainees in implementation science in cardiovascular, pulmonary, and sleep disorders through didactic work and mentored research projects. NIH/NHLBI 1K12HL 137862-01

Co-Principal Investigator (with Russell Glasgow), 0.6 calendar months

2017-2022

$2,937,246

*Enhancing cardiac rehabilitation adherence through home-based rehabilitation and behavioral nudges: ERA Nudge.* This purpose of this grant is to study the “choice” of home-based rehabilitation and the use of behavioral nudge messaging delivered through a smartphone application on the rate of enrollment and completion of rehabilitation in an underserved population. NIH/NHLBI 1R61HL143324-01

Co-investigator (Pamela Peterson, PI), 0.36 calendar months

2018 – 2023

$2,336,130 (total direct)

*Partnership in Education Training and Research Advancement (PETRA)*. This grant brings together four Zimbabwean university and two US medical school faculties to accelerate capacity development in health professions education and research, focusing on inter-professional education and implementation science. NIH/Fogarty International Center 1R25TW011215-01 (Hakim)

Co-Investigator (James Hakim, PI), 0.6 calendar months

2018-2023

$587,236 (total direct)

**COMPLETED FUNDING – Investigator-initiated grant projects**

*African Center for the Advancement of Research Excellence (AfriCARE).* The purpose of this exploratory grant is to establish priorities, strengthen collaborations, and build capacity to carry out research in cancer and cardiovascular disease in southern Africa, with the long term goal of establishing a comprehensive research center. NIH/NCI 1P20CA210677-01A1

Co-Principal Investigator (with Thomas Campbell, James Hakim, Margaret Borok), 0.6 calendar months

2017 – 2019

$531,880

*Creating a Patient Stakeholder Council and Patient Partner Network: Resources for CO**Patients*. This project will create a two-tier panel for patient engagement in the research process across two institutions, Denver Health and Kaiser Permanente of Colorado Institute for Health Research. PCORI 3023-DHHA

Principal Investigator, 0.6 calendar months

2016-2018  
$250,000

*Developing Infrastructure for Patient-Centered Outcomes Research at Denver Health.* This project combines research training for current physician staff with electronic data structure development and pilot projects in outcomes research. Its long term goal is to expand outcomes research capacity in a safety net healthcare system. AHRQ R24 HS022143-01

Principal Investigator, 2.4 calendar-months

2013-2018

$4,842,752

*Cerebrovascular, Heart Failure and Rheumatic Heart Disease Interventions Strategy (CHRIS) Initiative.* The goal of this project was to improve care for cardiovascular disease in Zimbabwe through in-country development of medical school faculty capacity. NIH/Fogarty International Center R24 TW008905-01

Co-Investigator (James Hakim, PI), 0.84 calendar-months

2010-2015

$2,500,000

*Improving symptoms and quality of life in advanced chronic heart failure.* The goal of this project was to conduct a randomized clinical trial to evaluate a palliative symptom management and psychosocial care intervention to improve quality of life in patients with heart failure. NIH/NINR R01 NR013422

Co-Investigator (David Bekelman, PI), 0.24 calendar-months

2011-2015

$1,313,833

*Advancing Measures for Risk Adjustment and Performance Assessment – Subproject 5*. This subproject of a Program Project based at Dartmouth investigates the impact of patient-reported measures on outcomes of care for elderly patients with multiple co-morbidities. NIH/NIA AGO 19783

Co-Investigator (Jonathan Skinner, PI), 0.36 calendar-months   
2013-2014  
$142,728 (DH)

*The Association between Providers' Ethnic/Racial Biases and Hypertension Control.* This project investigates physicians’ implicit racial and ethnic attitudes and their relationship to blood pressure control. NHLBI R01 HL88198-01A1

Co-Investigator (Irene Blair, PI)

2008-2013

$718,602

*An Intervention to Reduce the Effect of Racial and Ethnic Bias in Hypertension Care.* This project tested the effect of a novel intervention on patient-provider interaction and subsequent patient self-care behavior.

NHLBI R21 HL089623-01A2

Principal Investigator

2009-2012

$421,528

*Latinos Using Cardiovascular Health Actions to Reduce Risk.* NHLBI 1 U01 HL079160

Co-Principal Investigator

2004 - 2010

$2,985,310

*Interactive Voice Recognition Technology for the Management of Hypertension.*CO Dept of Public Health

Principal Investigator

2008-2009

$299,747

*Interactive Voice Recognition Technology for the Management of Hypertension.* CO Dept of Public Health

Co- Investigator

2006-2008

$1,146,826

**OTHER ACTIVITIES- Multicenter Clinical Research**

Death and Arrhythmic Events Committee, member. "Atrial fibrillation follow-up investigation of rhythm management (AFFIRM)", National Heart, Lung, and Blood Institute, 1997-2002.

**BIBLIOGRAPHY- Peer-reviewed journal articles**

1. **Havranek EP** and Dunbar DN. Exertional syncope caused by left main coronary artery spasm. Am Heart J 1992; 123:792-794.
2. **Havranek EP**, Bailey WN, and Adair OV. Left ventricular diastolic collapse in the absence of cardiac tamponade. Echocardiography 1993;10:1-4.
3. Read RA, Moore EE, Moore FA, **Havranek EP**, Veerakul G, Mestek M, Nademanee K. Intravascular ultrasound (IVUS) for the diagnosis of traumatic aortic disruption: a case report. Surgery 1993; 114:624-628.
4. **Havranek EP**. Management of the patient with myocardial infarction following hospital discharge. Am Fam Phys 1994; 49:1109-1119.
5. **Havranek EP**. The management of atrial fibrillation: new perspectives on a common problem. Am Fam Phys 1994; 959-968.
6. **Havranek EP**. Is cholesterol lowering an alternative to revascularization in some patients with coronary artery disease? Arch Int Med 1995; 155:670-675.
7. **Havranek EP**, Sherry PD. Left heart catheterization by direct puncture with two dimensional echocardiographic guidance. Cath Cardiovasc Design 1995; 35:358-361.
8. **Havranek EP**, Dwinnell B, Smith KS. Multiorgan failure after cardiac arrest in a 20 year-old man. Circulation 1995; 92:3139-3143.
9. Estacio R, Wolfel E, Reusch J, **Havranek E**, Regensteiner J, Johnson-Nagel N, Savage S, Schrier R. Effect of risk factors on exercise capacity in non-insulin dependent diabetes (NIDDM): role of hypertension, obesity, age, and ethnicity. Diabetes 1996; 45:79-85.
10. **Havranek EP**, Graham GW, Pan Z, Lowes B. Process and outcome of outpatient management of heart failure: a comparison of cardiologists and primary care providers. Am J Managed Care 1996; 2: 783-789.
11. **Havranek EP**, Nadamanee K, Grayburn PA, Eichhorn EJ. Endothelium-dependent vasorelaxation is impaired in cocaine arteriopathy. J Am Coll Cardiol 1996; 28: 1168-1174.
12. **Havranek EP**, Stevens E, Parker K, Abrams F. Determinants of mortality in elderly patients with heart failure: the role of angiotensin converting enzyme inhibitors. Arch Int Med 1998;158:2024-2028.
13. **Havranek EP**. Primary prevention of CHD: Nine ways to reduce risk. Am Fam Phys 1999; 59: 1455-1463.
14. **Havranek EP**, Thomas I, Smith WB, Ponce G, Bilsker M, Munger M, Lyver S, Aarons D, Graves T, Wolf RA for the Irbesartan CHF Group. Dose-related beneficial long-term hemodynamic and clinical effects of irbesartan in heart failure. J Am Coll Cardiol 1999: 1174-1181.
15. Estacio RO, Jeffers BW, **Havranek EP**, Krick D, Samson O, Schrier RW. Deletion poymorphism of the angiotensin converting enzyme (ACE) gene is associated with an increase in left ventricular mass in males with NIDDM. Am J Hypertension 1999; 12: 637-42.
16. **Havranek EP**, Lowes BL, Abraham WT, McGovern K. Utilities are valid measures of health related quality of life in patients with heart failure. J Cardiac Failure 1999; 5: 85-91.
17. **Havranek EP**, Ware MG, Lowes BL. The prevalence of depression in patients with heart failure. Am J Cardiol 1999; 84: 348-350.
18. Krumholz HM, Baker DW, Ashton CM, Dunbar SB, Friesinger GC, **Havranek EP**, Hlatky MA, Konstam M, Ordin DL, Pina IL, Pitt B, Spertus JA. Evaluating quality of care for patients with heart failure. Circulation 2000; 101: e122-e140.
19. Quality of Care and Outcomes Research in CVD and Stroke Working Group. Measuring and improving quality of care: a report from the American Heart Association/American College of Cardiology First Scientific Forum on Healthcare Quality in Cardiovascular Disease and Stroke. Circulation 2000; 101: 1483-93.
20. Sauaia A, Ralston D, Schluter WW, Marciniak TA, **Havranek EP**, Dunn TR. Influencing care in acute myocardial infarction: a randomized trial comparing two types of intervention. Am J Medical Quality 2000; 15; 197-206.
21. **Havranek EP**, Lapuerta P, Simon TA, L’Italien G, Block AJ, Rouleau JL. A health perception score predicts cardiac events in patients with heart failure: results from the IMPRESS trial. J Cardiac Failure 2001; 7: 153-7.
22. Krantz MJ , Woods JE, **Havranek EP**, Linas S. Simultaneous malignant hypertension and cardiac tamponade. Am J Kidney Dis 2002; 39(3): E17.
23. Masoudi FA, **Havranek EP**, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Failure Reviews 2002; 7: 9-16.
24. **Havranek EP**, Masoudi FA, Westfall K, Wolfe P, Ordin DL, Krumholz HM. The spectrum of heart failure in older adults: Results from the National Heart Failure project. Am Heart J 2002; 143: 412-7.
25. Gottlieb SS, Brater DC, Thomas I, **Havranek E**, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, and Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002; 105: 1348-1353.
26. Masoudi FA, **Havranek EP**, Smith G, Fish R, Krumholz HM, Steiner JF, Ordin DL, Krumholz HM. Gender, age and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003; 41: 217-23.
27. **Havranek EP**, Masoudi FA, Rumsfeld JS, Steiner JF. A broader paradigm for understanding and treating heart failure. J Cardiac Failure; 2003; 9:147-152.
28. Lindenfeld J, Fiske KS, Stevens BR, Debuhr J, **Havranek EP**, Abrams FR. Age, but not sex, influences the measurement of ejection fraction in elderly patients hospitalized for heart failure. J Cardiac Failure 2003; 9: 100-106.
29. Rathore SS, Foody JM, Wang Y, Smith GL, Herrin J, Masoudi FA, Wolfe P, **Havranek EP**, Ordin DL, Krumholz HM. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA 2003; 289: 2517-2524.
30. **Havranek EP**, Esler A, Mehler PS, Estacio RO, Schrier RW. Differential effects of anti-hypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. Am Heart J 2003; 145: 993-8.
31. Masoudi FA, Wang, Y, Inzucchi SE, Setaro JF, **Havranek EP**, Foody JM, Krumholz HM. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003; 290; 81-5.
32. Masoudi FA, **Havranek EP**, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003; 146: 250-7.
33. **Havranek EP**, Krumholz HM, Dudley RA, Adams K, Gregory D, Lindenfeld JA, Massie B, Pina I, Restaino S, Rich MW, Konstam MA. Aligning quality and payment for heart failure care: defining the challenges. J Cardiac Failure 2003; 9: 251-4.
34. Rumsfeld JS, **Havranek EP**, Masoudi FM, Peterson ED, Jones P, Tooley JF, Krumholz HM, Spertus JA for the Cardiovascular Outcomes Research Consortium (CORC). Depressive symptoms are the strongest predictor of short-term declines in health status in patients with heart failure. J Am Coll Cardiol 2003; 42: 1811-7.
35. Curtis JP, Wang Y, Portnay EL, Masoudi FA, **Havranek EP**, Krumholz HM. Aspirin, ibuprofen, and mortality after myocardial infarction: a retrospective cohort analysis. BMJ 2003; 327: 1322-3.
36. Foody JM, Rathore SS, Wang Y, Herrin J, Masoudi FM, **Havranek EP**, Radford MJ, Krumholz HM. Predictors of cardiologist care for older patients hospitalized with heart failure. Am Heart J 2004; 147:66-73.
37. Hockensmith ML, Estacio RO, Mehler P, **Havranek EP**, Ecder ST, Lundgren RA, Schrier RW. Albuminuria is a predictor of heart failure in patients with type 2 diabetes. J Cardiac Failure 2004; 10: 126-131.
38. Steinberg J, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell WB, **Havranek E**, Murray K, Olshansky B, O’Neil G, Sami M, Schmidt S, Storm R, Zabalgoita M, Miller J. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109: 1973 – 1980.
39. Krantz MJ, **Havranek EP**, Mehler PS, Haynes DK, Long CS. Impact of a cardiac risk reduction program in vulnerable patients hospitalized with coronary artery disease. Pharmacotherapy 2004; 24: 768-775.
40. **Havranek EP**, Wolfe P, Masoudi FA, Rathore SS, Krumholz HM, Ordin DL. The provider and hospital characteristics associated with geographic variation in the evaluation and management of elderly patients with heart failure. Arch Int Med 2004; 164: 1186-91.
41. Masoudi FA, Rathore SR, Wang YF, **Havranek EP**, Curtis JP, Foody JM, Krumholz HM. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation 2004; 110: 724-31.
42. **Havranek EP**, Simon TA, L’Italien G, Smitten A, Hauber AB, Chen R, Lapuerta P. The relationship between health perception and utility in heart failure patients in a clinical trial: Results from an OVERTURE sub-study. J Cardiac Failure 2004; 10: 339-43.
43. Masoudi FA, Rumsfeld JS, **Havranek EP**, House JA, Peterson ED, Krumholz HM, Spertus JA. Age, functional capacity, and health-related quality of life in patients with heart failure. J Cardiac Failure 2004; 10: 368-73.
44. Rathore SS, Masoudi FA, **Havranek EP**, Krumholz HM. Regional variations in racial differences in the treatment of elderly patients hospitalized with acute myocardial infarction. Am J Med 2004; 117: 811-22.
45. **Havranek EP**, Spertus JA, Masoudi FA, Jones PG, Rumsfeld JS. Predictors of the onset of depressive symptoms in heart failure patients. J Am Coll Cardiol 2004; 44: 2333-8.
46. Rathore SS, Foody JM, Wang Y, Herrin J, Masoudi FA, **Havranek EP**, Ordin DL, Krumholz HM. Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. Am Heart J 2005; 149: 121-8.
47. Masoudi FA, Inzucchi SE, Wang Y, **Havranek EP**, Foody JM, Krumholz HK. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005 111: 583 - 590.
48. Hauptman PJ and **Havranek EP**. Integrating palliative care into heart failure care. Arch Int Med 2005; 165: 374-8.
49. Smith GL, Shlipak MG, **Havranek EP**, Masoudi FA, McClellan WM, Foody JM, Rathore SS, Krumholz HM. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation 2005; 111: 1270-7.
50. Krantz MJ, Zwang O, Rowan SB, Cleary B, Chu E, Reid MB, Cantrill SV, **Havranek EP**, Albert RK. A cooperative care model: cardiologists and hospitalists reduce length of stay in a chest pain observation unit. Crit Pathways in Cardiol 2005; 4: 55-58.
51. Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, **Havranek EP** and Krumholz HM. Insulin sensitizing anti-hyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project. Diabetes Care, 2005; 28:1680-9.
52. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, **Havranek EP**, Krumholz HM. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005; 111: 3078-86.
53. Masoudi FA, Gross CP, Wang Y, Rathore SS, **Havranek EP**, Foody JM, Krumholz HM. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 2005;112:39-47.
54. Luther SA, McCullough PA, **Havranek EP**, Rumsfeld JS, Jones PG, Heidenreich PA, Peterson ED, Rathore SS, Krumholz HM, Weintraub WS, Spertus JA, Masoudi FA. The relationship between B-type natriuretic peptide and health status in patients with heart failure. J Cardiac Failure 2005; 11: 414-21.
55. Strickberger SA, Conti J, Daoud EG, **Havranek EP**, Mehra MR, Piña IL, Young J. Scientific advisory: patient selection for cardiac resynchronization therapy. Circulation 2005; 111: 2146-2150.
56. Masoudi FA, Pam Wolfe P, **Havranek EP**, Rathore SR, Foody JM, Krumholz HM. Aspirin use in older patients with heart failure and coronary artery disease: National prescription patterns and relationship with mortality. J Am Coll Cardiol 2005; 46: 955-962.
57. Foody JM, Rathore SS, Wang Y, Herrin J, Masoudi J, Masoudi FA, **Havranek EP**, Krumholz HM. Physician specialty and mortality among elderly patients hospitalized with heart failure. Am J Med 2005; 118: 1120-5.
58. Radford MJ, Arnold JM, Bennett SJ, Cinquegrani MP, Cleland JGF, **Havranek EP**, Heidenreich PA, Rutherford JD, Spertus JA, Stevenson LW. ACC/AHA key data elements and data definitions for measuring the clinical management and outcomes of patients with heart failure: a report of the ACC/AHA Task Force on Clinical Data Standards (Heart Failure Data Standards Writing Committee). J Am Coll Cardiol 2005; 46: 1179 –207 and Circulation 2005; 112: 1888-1916.
59. Masoudi FA, Baillie CA, Wang Y, Bradford WD, Steiner JF, **Havranek EP**, Foody JM, Krumholz HM. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med 2005; 165: 2069-2076.
60. Ko DT, Tu JV, Masoudi FA, Wang Y, **Havranek EP**, Rathore SS, Newman AM, Donovan LR, Lee DS, Foody JM, Krumholz HM. Quality of care and outcomes of older patients with heart failure hospitalized in the United States and Canada. Arch Intern Med 2005; 165: 2486-2492.
61. Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM, **Havranek EP**, Krumholz HM. Anemia and outcomes in patients with heart failure: A study from the National Heart Care Project. Arch Intern Med 2005; 165: 2237-2244.
62. Heidenreich PA, Spertus, JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore SS, Peterson ED, Masoudi FA, Krumholz HM, **Havranek EP**, Conard MW, Williams RE. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol 2006;47 752-756.
63. Morgan AL, Masoudi FA, **Havranek EP**, Jones PG, Peterson PN, Krumholz HM, Spertus JA, Rumsfeld JS. Difficulty taking medications, depression, and health status in heart failure patients. J Cardiac Failure 2006; 12: 54-60.
64. Riegel B, Moser DK, Powell M, Rector TS, **Havranek EP**. Non-pharmacologic care by heart failure experts. J Cardiac Failure 2006; 12: 149.e1-149.e11.
65. Foody JM, Shah R, Galusha D, Masoudi FA, **Havranek EP**, Krumholz HM. Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006; 113: 1086-1092.
66. Foody JM, Rathore SS, Galusha D, Masoudi FA, **Havranek EP**, Radford MJ, Krumholz HM. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. J Am Geriatr Sic 2006; 54: 421-30.
67. Smith GL, Shlipak MG, **Havranek EP**, Foody JM, Masoudi FA, Rathore SS, Krumholz HM. Serum urea nitrogen, creatinine, and estimators of renal function: Mortality in older patients with cardiovascular disease. Arch Intern Med 2006; 166: 1134-1142.
68. Rathore SS, Masoudi FA, Wang Y, Curtis JP, Foody JM, **Havranek EP**, Krumholz HM. Socioeconomic status, treatment, and outcomes among elderly patients hospitalized with heart failure: Findings from the National Heart Failure Project. Am Heart J 2006; 152: 371-378.
69. Masoudi FA, Foody JM, **Havranek EP**, Wang Y, Radford MJ, Allman RM, Gold J, Wiblin T, Krumholz HM. Trends in acute myocardial infarction in four U.S. states between 1992 and 2001: Clinical characteristics, quality of care, and outcomes. Circulation 2006; 114: 2806-14.
70. Conard M, Haddock CK, Carlos Poston WS, **Havranek EP**, McCullough P, Spertus J. Impact of obesity on the health status of heart failure patients. J Cardiac Failure 2006; 12: 700-6.
71. Ko DT, Krumholz HM, Wang Y, Foody JM, Masoudi FA, **Havranek EP**, You JJ, Alter DA, Stukel TA, Newman AM, Tu JV. Regional differences in process of care and outcomes for older acute myocardial infarction patients in the United States and Ontario, Canada. Circulation 2007; 115: 196-203.
72. Radford MJ, Heidenreich PA, Bailey SR, Goff DC, Grover FL, **Havranek EP**, Kuntz RE, Malenka DJ, Peterson ED, Redberg RF, Roger VL. ACC/AHA 2007 Methodology for the development of clinical data standards: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. J Am Coll Cardiol 2007; 49: 830-837.
73. Greenberg B, Thomas I, Banish D, Goldman S, **Havranek E**, Massie BM, Zhu Y, Ticho B, Abraham WT. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: Results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol 2007;50 600-606.
74. Bekelman DB, **Havranek EP**, Becker DM, Kutner JS, Peterson PN. Wittstein IS, Gottlieb SH, Yamashita TE, Fairclough DL, Dy SM. Symptoms, depression, and quality of life in patients with heart failure. J Cardiac Failure 2007; 13: 643-8.
75. Plomondon ME, Magid DJ, Masoudi FA, Jones PG, Barry LC, **Havranek E**, Peterson ED, Krumholz HM, Spertus JA, Rumsfeld JS. Association between angina and treatment satisfaction after myocardial infarction. J Gen Int Med 2008; 23: 1-6.
76. Ho PM, Eng MH, Rumsfeld JS, Spertus JA, Peterson PN, Jones PG, Peterson ED, Alexander KP, **Havranek EP**, Krumholz HM, Masoudi FA. The influence of age on health status outcomes after acute myocardial infarction. Am Heart J 2008; 155: 855-61.
77. Hanratty R, Estacio RO, Dickinson LM, Chandramouli V, Steiner JF, **Havranek EP**. Development of a hypertension registry for population management from electronic data in a safety net institution. J Health Care Poor Underserved 2008; 19: 452-65.
78. Krantz MJ, **Havranek EP**, Haynes DK, Smith I, Bucher-Bartelson B, Long CS. Inpatient initiation of blockade plus nurse management in vulnerable heart failure patients: A randomized study. J Cardiac Failure 2008; 14: 303-9.
79. **Havranek EP**, Emsermann CDB, Froshaug DN, Masoudi FA, Krantz MJ, Hanratty R, Estacio RO, Dickinson LM, Steiner JS. Thresholds in the relationship between mortality and left ventricular hypertrophy defined by electrocardiography. J Electrocardiol 2008; 41: 342-50.
80. Cleary BS, Keniston A, **Havranek EP**, Albert RK. Intimate partner violence in women hospitalized on an internal medicine service: prevalence and relationship to responses to the review of systems. J Hosp Med 2008; 3: 299-307.
81. **Havranek EP**, Froshaug DN, Emsermann CDB, Hanratty R, Krantz MJ, Masoudi FA, Dickinson LM, Steiner JS. Left ventricular hypertrophy and cardiovascular mortality by race and ethnicity. Am J Med 2008; 121: 870-5.
82. Padilla R, Gutierrez Ragunath S, Fernald D, **Havranek E**, Steiner J, Bull S. Designing a cardiovascular disease prevention web site for Latinos: Qualitative community feedback. Health Promotion Practice 2010; 11: 140-7.
83. **Havranek EP**, Wolfe P, Masoudi FA, Foody JM, Rathore SS, Krumholz HM. The relationship between reimbursement and quality of care for patients hospitalized with heart failure. The Open Health Services and Policy Journal 2008; 1: 27-33. http://www.bentham.org/open/tohspj/openaccess2.htm
84. Kosiborod M, Inzucchi SE, Spertus JA, Wang Y, Masoudi FA, **Havranek EP**, Krumholz HM. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. Circulation 2009; 119: 1899-1907.
85. Krumholz HM, Wang Y, Chen J, Drye EE, Spertus JA, Ross JS, Curtis JP, Nallamothu BK, Lichtman JH, **Havranek EP**, Masoudi FA, Radford MJ, Han LF, Rapp MT, Straube BM, Normand ST. Reduction in acute myocardial infarction mortality in the United States: Risk-standardized mortality rates from 1995-2006. JAMA 2009; 302: 767-773.
86. Bekelman DE, Rumsfeld JS, **Havranek EP**, Yamashita TE, Hutt E, Gottlieb SH, Kutner JS. Symptom burden, depression, and spiritual well-being: A comparison of heart failure and advanced cancer patients. J Gen Int Med 2009; 5: 592-8.
87. Steiner JF, Ho PM, Beaty BL, Dickinson LM, Hanratty R, Zeng C, Tavel HM, **Havranek EP**, Magid DJ, Estacio RO. Socio-demographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ CV Quality Outcomes 2009; 2: 451-457.
88. Riegel B, Moser DK, Anker SD, Appel LJ, Dunbar SB, Grady KL, Gurvitz MZ, **Havranek EP**, Lee CS, Lindenfeld J, Peterson PN, Pressler SJ, Schocken DD, Whellan DJ; on behalf of the American Heart Association Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Nutrition, Physical Activity, and Metabolism, and Interdisciplinary Council on Quality of Care and Outcomes Research. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation 2009; 120: 1141-1163.
89. Rathore SS, Curtis JP, Nallamothu BK, Wang Y, Foody JM, Kosiborod M, Masoudi FA, **Havranek EP**, Krumholz HM. Association of door-to-balloon time and mortality in elderly patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2009; 104: 1198-1203.
90. Hanratty R, Chonchol M, Dickinson LM, Beaty BL, Estacio RO, MacKenzie TD, Hurley LP, Linas SL, Steiner JF, **Havranek EP**. Incident chronic kidney disease and the rate of kidney function decline in individuals with hypertension. Nephrology Dialysis Transplantation 2010; 25: 801-7.
91. Hurley LP, Dickinson LM, Estacio RO, Steiner JF, **Havranek EP**. Prediction of cardiovascular death in racial/ethnic minorities using Framingham risk factors. Circ Cardiovac Qual Outcomes 2010; 3: 181-187.
92. Lipska KJ, Wang Y, Kosiborod M, Masoudi FA, **Havranek EP**, Krumholz HM Inzucchi SE. The discontinuation of anti-hyperglycemic therapy and clinical outcomes in older patients with diabetes after acute myocardial infarction. Circ CV Quality Outcomes 2010; 3: 236-42.
93. Blair IV, Judd CM, **Havranek EP**, Steiner JF. Using community data to test the discriminant validity of ethnic/racial group IATs. J Psychol 2010; 218: 36–43.
94. Lambert-Kerzner AC, **Havranek EP**, Plomondon ME, Albright K, Moore A, Gryniewicz K, Magid D, Ho PM. Patients' perspectives on a multifaceted intervention with a focus on technology: A qualitative analysis. Circ CV Quality Outcomes 2010; 3: 668-674.
95. Padilla R, Davidson A, **Havranek EP**, Steiner JF, Beaty BL, Bull S. A comparison of different measures of acculturation with cardiovascular risk factors In Latinos with hypertension. J Immigrant Minority Health 2011; 13: 284.
96. Krantz MJ, Long CS, Hosakawa P, Karamkhani E, Dickinson LM, Estacio RO, Masoudi FA, **Havranek EP**. Pulse wave velocity and carotid atherosclerosis in white and Latino patients with hypertension. BMC Cardiovascular Disorders 2011, 11:15. *Available at:* http://www.biomedcentral.com/1471-2261/11/15
97. Magid DJ, Ho PM, Olson KL, Brand DW, Welch LK, Snow KE, Lambert-Kerzner AC, Plomondon ME, **Havranek EP**. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011;17(4):e96-e103.
98. Fitzgerald AA, Powers JD, Ho MP, Maddox TM, Peterson PN, Allen LA, Masoudi FA, Magid DJ, **Havranek EP**. The impact of medication non-adherence on hospitalizations and mortality in heart failure. J Cardiac Failure 2011; 17: 664-669.
99. Welch L, Olson KL, Snow K, Pointer L, Lambert-Kerzner A, **Havranek EP**, Magid DJ, Ho MP. Systolic blood pressure control after participation in a hypertension intervention study. Am J Managed Care 2011; 17: 473-478.
100. Pereira RI, Wang CCL, Hosokawa P, Dickinson LM, Chonchol M, Krantz MJ, Steiner JF, Bessesen D, **Havranek EP,** Long CS. Circulating adiponectin levels are lower in Latino versus non-Latino white patients at risk for cardiovascular disease independent of adiposity measures. BMC Endocrine Disorders 2011; 11:13. *Available at:* <http://www.biomedcentral.com/1472-6823/11/13>
101. Hanratty R, **Havranek EP,** Steiner JF, Chonchol M, Dickinson LM, Powers JD, Ho PM, Magid DJ. Relationship between blood pressure and incident chronic kidney disease in hypertensive patients. Clin J Am Soc Nephrol 2011: 6. *Available at:* [http://cjasn.asnjournals.org/cgi/content/abstract/CJN.02240311](file:///C:\cgi\content\abstract\CJN.02240311)
102. Peterson PN, Campagna EJ, Maravi M, Allen LA, MD, Bull S, Steiner JF, **Havranek EP**, Dickinson LM, Masoudi FA. Acculturation and outcomes among patients with heart failure. Circ Heart Fail 2012; 5: 160-6.
103. Allen LA, Stevenson LW, Grady KL, Goldstein NE, Matlock DD, Arnold RM, Cook NR, Felker GM, Francis GS, Hauptman PJ, **Havranek EP**, Krumholz HM, Mancini D, Riegel B, Spertus JA. Shared decision making in advanced heart failure. A scientific statement from the American Heart Association. Circulation 2012; 125: 1928-52.
104. Schroeder EB, Hanratty R, Beaty BL, Bayliss EA, **Havranek EP**, Steiner JF. Simultaneous control of diabetes, hypertension, and hyperlipidemia in two health systems. Circ CV Quality Outcomes 2012; 5:5 645-653.
105. **Havranek EP**, Hanratty R, Tate C, Dickinson LM, Steiner JF, Cohen G, Blair IA. The effect of values-affirmation on race-discordant patient-provider communication. Arch Int Med 2012; 172(21):1662-7.
106. Blair IV, **Havranek EP**, Price DW, Hanratty R, Fairclough DL, Farley T, Hirsh HK, Steiner JF. Assessment of biases against Latinos and African Americans among primary care providers and community members. Am J Public Health 2013; 103: 92-8.
107. Blair IV, Steiner JF, Fairclough D, Hanratty R, Price DW, Katz HE, Wright LA, Bronsert M, Karimkhani E, Magid DJ, **Havranek EP**. Clinicians’ implicit ethnic/racial bias predicts patients’ perceptions of care among black but not Latino patients. Ann Fam Med 2013; 11: 43-52.
108. Blair IV, Steiner JF, Hanratty R, Price DW, Fairclough DL, Daugherty SL, Bronsert M, Magid DJ, **Havranek EP**. An investigation of associations between clinicians’ ethnic or racial bias and hypertension treatment, medication adherence and blood pressure control. J Gen Int Med 2014; 29(7): 987-995. PMID: 24549521.
109. Lambert-Kerzner A, **Havranek EP,** Plomondon ME, Fagan KM, McCreight MS, Fehling KB, Williams DJ, Hamilton AB, Albright K, Blatchford PJ, Mihalko-Corbitt R, Bryson CL, Bosworth HB, Kirshhner M, Del Giacco EJ, Ho M. Perspectives of patients on factors relating to adherence to post-acute coronary syndrome medical regimens. Patient Preference and Adherence 2015; 9: 1053-9. <http://www.dovepress.com/articles.php?article_id=22788&l=9xaWgUF48BcEW1Z7852nxCNg440659>
110. **Havranek EP**, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, Davey-Smith G, Dennison-Himmelfarb CR, Lauer MS, Lockwood DW, Rosal M, Yancy CW. Social determinants of risk and outcomes for cardiovascular disease: A Scientific Statement From the American Heart Association. Circulation 2015; 132:9 873-898.
111. Krantz MJ, **Havranek EP**, Pereira RI, Beaty B, Mehler PS, Long CS. Effects of omega-3 fatty acids on arterial stiffness in patients with hypertension: a randomized pilot study. J Negat Results Biomed 2015; 14(1): 21. PMID: 26631058
112. [Pereira](http://www.mdpi.com/search?authors=Rocio%20I.%20Pereira&orcid=) RI, [Low Wang](http://www.mdpi.com/search?authors=Cecilia%20C.%20Low%20Wang&orcid=) CC, Wolfe P, **Havranek EP**, [Long](http://www.mdpi.com/search?authors=Carlin%20S.%20Long&orcid=) CS, [Bessesen](http://www.mdpi.com/search?authors=Daniel%20H.%20Bessesen&orcid=) DH. Associations of adiponectin with adiposity, insulin sensitivity, and diet in young, healthy, Mexican Americans and non-Latino white adults. Int J Environmental Res Pub Health, Int J Environ Res Public Health. 2015 Dec 22;13(1). pii: E54.PMID:26703682 <http://www.mdpi.com/1660-4601/13/1/54>
113. Martin SS, Faridi KF, Joshi PH, Blaha MJ, Kulkarni KR, Khokhar AA, Maddox TM, **Havranek EP**, Toth PP, Tang F, Spertus JA, Jones SR. Remnant lipoprotein cholesterol and mortality after acute myocardial infarction: Further evidence for a hypercholesterolemia paradox From the TRIUMPH Registry. Clin Cardiol. 2015; 38(11): 660-7. PMID: 26459191
114. Pflederer MC, Long CS, Beaty B, **Havranek EP**, Mehler PS, Keniston A, and Krantz MJ. **Longitudinal changes in vascular risk markers and mortality rates among a Latino population with hypertension.** Texas Heart Inst J 2016; 43(2): 131-136.
115. Moore S, Fischer I, **Havranek E**. Translating health services research into practice in the safety net. Health Serv Res 2016; 51(1): 16-31*.* PMID:26646189
116. Fischer HH, Fischer IP, Pereira IR, Furniss AL, Rozwadowski JM, Moore SL, Durfee MJ, Raghunath SG, Tsai AG, **Havranek EP**. Text message support versus usual care for weight loss in patients with prediabetes: A randomized clinical trial. Diabetes Care 2016; 39(8): 1364-70.
117. Bekelman DB, Allen LA, Peterson J, Hattler B, **Havranek EP**, Fairclough DL, McBryde CF, Meek PM. Rationale and study design of a patient-centered intervention to improve health status in chronic heart failure: the Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) randomized trial. Contemp Clin Trials. 2016; 51: 1-7. PMID: 27634669*.*
118. Ritchie ND, Christoe-Frazier L, McFann KK, **Havranek EP**, Pereira RI. Effect of the National Diabetes Prevention Program on weight loss for English- and Spanish-speaking Latinos. Am J Health Promot. 2018; 32(3): 812-815. PMID: 28320212
119. Trent SA, Johnson MA, Morse EA, **Havranek EP**, Haukoos JS. Patient, provider, and environmental factors associated with adherence to cardiovascular and cerebrovascular clinical practice guidelines in the ED. Am J Emerg Med. 2018; 36(8):1397-1404. PMID:29402689
120. Beck A, Davidson AJ, Xu S, Oronce Irwin C, Durfee MJ, Steiner JF, **Havranek E**. A multilevel analysis of individual, health system, and neighborhood factors associated with depression within a large metropolitan area. J Urban Health 2017; 94(6):780-790.
121. Daugherty SL, Blair IV, **Havranek EP**, Furniss A, Dickinson M, Karimkhani E, Main DS, and Masoudi FA. Implicit gender bias and the use of cardiovascular tests among cardiologists. J Am Heart Assoc 2018;6:e006872.
122. Bekelman DB, Allen LA, McBryde CF, Hattler B, Fairclough DL, **Havranek EP**, Turvey C, Meek PM. Improving health status in chronic heart failure: The Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) randomized clinical trial. JAMA: Intern Med2018; 178(4): 511-519. PMID: 29482218
123. Hakim JG, Chidzonga MM, Borok MZ, Nathoo KJ, Matenga J, **Havranek E**, Cowan F, Abas M, Aagaard E, Connors S, Nkomani S, Ndhlovu CE, Matsika A, Barry M, Campbell TB. Medical Education Partnership Initiative (MEPI) in Zimbabwe: Outcomes and Challenges. Glob Health Sci Pract 2018; 6(1):82-92. PMID:29602867
124. Ritchie ND, Carroll JK, Holtrop JS, **Havranek EP**. Effects of physical activity goal attainment on engagement and outcomes in the National Diabetes Prevention Program. Transl Behav Med. 2018; 8(6): 932-937 PMID: 29669050
125. Magnani JW, Mujahid MS, Aronow HD, Cené CW, Dickson VV, **Havranek E**, Morgenstern LB, Paasche-Orlow MK, Pollak A, Willey JZ. Health literacy and cardiovascular disease: Fundamental relevance to primary and secondary prevention: A Scientific Statement from the American Heart Association. Circulation. 2018; 138(2):e48-e74. PMID: 29866648
126. Davidson AJ, Xu S, Oronce CIA, Durfee MJ, McCormick EV, Steiner JF, **Havranek E**, Beck A. Monitoring depression rates in an urban community: Use of electronic health records. J Public Health Manag Pract. 2018; 24(6): E6-E14. PMID: 29334514
127. Doyle R, Albright K, Hurley LP, Chávez C, Stowell M, Dircksen S, **Havranek EP**, Anderson M. Patient perspectives on a text messaging program to support asthma management: A qualitative study. Health Promot Pract 2018: 1524839918770209. [Epub ahead of print] PMID:29732922
128. Trent SA, **Havranek EP**, Ginde AA, Haukoos JS. Effect of Audit and Feedback on Physician Adherence to Clinical Practice Guidelines for Pneumonia and Sepsis. Am J Med Qual. 2019; 34(3): 217-225. PMID: 30205697
129. Trent SA, Jarou ZJ, **Havranek EP**, Ginde AA, Haukoos JS. Variation in Emergency Department Adherence to Treatment Guidelines for Inpatient Pneumonia and Sepsis: A Retrospective Cohort Study. Acad Emerg Med. 2018 Oct 21. [Epub ahead of print] PMID: 30343515
130. Trent SA, Morse EA, Ginde AA, **Havranek EP**, Haukoos JS. Barriers to prompt presentation to emergency departments in Colorado after onset of stroke symptoms. West J Emerg Med. 2019;20(2): 237-243. PMID: 30881542
131. **Havranek EP.** Epidemiology of heart disease: The influence of socioeconomic position. Trends in Cardiovascular Medicine 2019; 29(5): 298-303. PMID: 30270096
132. Daugherty SL, Vuputurri S, Hanratty R, Steiner JF, Maertens JA, Blair IV, Dickinson LM, Helmkamp L, **Havranek EP**. Using values affirmation to reduce the effects of stereotype threat on hypertension disparities: Rationale and protocol for the multicenter randomized HYpertension and VALUEs (HYVALUE) Trial. *JMIR Res Protoc*, 2019; 8(3): e12498
133. Perman SM, Shelton SK, Knoepke C, Rappaport K, Matlock DD, Adelgais K, **Havranek EP**, Daugherty SL. Public perceptions on why women receive less bystander cardiopulmonary resuscitation than men in out-of-hospital cardiac arrest. Circulation 2019; 139(8): 1060-1068. PMID: 30779655
134. Cervantes L, Chonchol M, Hasnain-Wynia R, Steiner JF, **Havranek E**, Hull M, Rice J, Kendrick J, Alamillo X, Camacho C, Fischer S. Peer navigator intervention for Latinos on hemodialysis: A single-arm clinical trial. J Palliat Med. 2019 Jan 31. [Epub ahead of print]. PMID: 30702365
135. Perman SM, SiryBJ, Ginde AA,Grossestreuer AV, Abella BS, Daugherty SL, **Havranek EP**. Sex differences in “Do Not Attempt Resuscitation” orders after out-of-hospital cardiac arrest and the relationship to critical hospital interventions. Clin Therapeutics 2019 Apr 20. [Epub ahead of print]*.* PMID: 31047712
136. Rinehart DJ, Leslie S, Durfee MJ, Cox-Martin M, Stowell M, Thomas-Gale T, Shlay JC, **Havranek EP**. Acceptability and efficacy of a sexual health texting intervention designed to support adolescent females. Academic Pediatrics 2020; 20(4): 475-84. <https://doi.org/10.1016/j.acap.2019.09.004>
137. Perman S, Beaty B, Daugherty S, **Havranek E**, Haukoos J, Juarez-Colunga E, Bradley S, Fendler T, Chan P. Do sex differences exist in the establishment of "Do Not Attempt Resuscitation" orders and survival in patients successfully resuscitated from in-hospital cardiac arrest? J Am Heart Assoc 17 Feb 2020 [http://ahajournals.org/doi/10.1161/JAHA.119.014200](http://click.heartemail.org/?qs=8c522f2ba92dd31c1d4915d7ae6f4f9b9699071fb29297e4f06fbf59385de815c0456f106cc526d1a14423159ea896c95f51945bf06ba6f2)*.*
138. Vogel JA, Rising KL, Jones J, Bowden ML, Ginde AA, **Havranek EP**. Reasons patients choose the emergency department over primary care: a qualitative metasynthesis. J Gen Intern Med 2019; 34(11): 2610-2619. *Epub 19 Aug 2019*. PMID31428988
139. Mould-Millman NK, Dixon J, Lamp A, de Vries S, Beaty B, Finck L, Colborn K, Moodley K, Skenadore A, Glasgow RE, **Havranek EP**, Bebarta VS, Ginde AA. A single-site pilot implementation of a novel trauma training program for prehospital providers in a resource-limited setting. Pilot Feasibility Stud. 2019 Dec 5;5:143. PMID31844551
140. Mansoori J, Linde-Zwirble W, Hou P, **Havranek E**, Douglas IS. Variability in usual care fluid resuscitation and risk-adjusted outcomes for mechanically ventilated patients in shock. Crit Care 2020. *Epub 28 Jan 2020.* <https://doi.org/10.1186/s13054-020-2734-9>
141. Rinehart DJ, Leslie SE, Kuka K, Doyle R, Stowell M, Thomas-Gale T, Shlay JC, **Havranek EP**, Albright K. Adolescent female perspectives in an urban safety net: Developing an intervention focusing on sexual health and text-messaging. J Health Care Poor Underserved 2020. *Accepted for publication.*

**BIBLIOGRAPHY- Multi-center trial investigator**

1. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
2. Horton ES, Whitehouse F, Ghazi MN, Venable TC, Whitcomb RW, for the Troglitazone Study Group. Troglitazone in combination with sulfonylurea restores glycemic control in patients with Type 2 diabetes. Diabetes Care 1998; 21: 1462-9.
3. The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 2000; 355: 337-45.
4. Pitt B, O’Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS for the QUIET Study Group. The Quinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function Am J Cardiol 2001; 87: 1058-1063.
5. McClean DR, Ikram H, Mehta S, Heywood JT, Rousseau MF, Niederman AL, Sequeira RF, Fleck E, Singh SN, Coutu B, Hanrath P, Komajda M, Bryson CC, Qian C, and Hanyok JJ for the Omapatrilat Hemodynamic Study Group. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. J Am Coll Cardiol 2002; 39: 2034-41.
6. The AFFIRM Investigators. Baseline characteristics of patient with atrial fibrillation: The AFFIRM Study. Am Heart J 2002; 143: 991-1001.
7. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J-L, Swedberg K for the OVERTURE Study Group. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002; 106: 920-926.
8. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 1825-1833.
9. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-698.
10. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, McCullough PA, Pina I, Tooley J, Weintraub WS, Rumsfeld JS for the Cardiovascular Outcomes Research Consortium. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J 2005; 150: 707-15.

**BIBLIOGRAPHY- Books, Chapters, Editorials, Secondary Publications, Letters to the Editor**

1. **Havranek EP**. Ethics of patient-sponsored research. N Engl J Med 1987;317:172.
2. **Havranek EP**. Lipid levels and affluent diets. N Engl J Med 1992;327:53.
3. **Havranek EP** and Adair OV. “Ischemic heart disease", in Emergency Medicine Secrets, Hanley and Belfus, Philadelphia, 1993.
4. Adair OV and **Havranek EP**, eds, Cardiology Secrets, Hanley and Belfus, Philadelphia, 1994.
5. **Havranek EP**. Bedside hemodynamic monitoring. Chapter 4 ibid.
6. **Havranek EP**. Congestive heart failure. Chapter 21. ibid.
7. **Havranek EP**. Traumatic heart disease. Chapter 31. ibid.
8. **Havranek EP**. Aortic stenosis and regurgitation. Ch. 43. ibid.
9. Myers AM and **Havranek EP**. Myocardial infarction occurring three years after mantle irradiation in a 32 year old woman with severe hypercholesterolemia. Am J Hematol, 1998;57:180-81.
10. **Havranek EP**. The effects of the angiotensin II receptor antagonist irbesartan in patients with CHF. Cardiovascular Reviews and Reports 1998;19:29-33.
11. **Havranek EP** and Abraham WT. The health care economics of heart failure. Heart Failure 1998; 14:10-18.
12. **Havranek EP**. “Ischemic heart disease", in Emergency Medicine Secrets, 2d ed. Hanley and Belfus, Philadelphia, 1999.
13. **Havranek EP**, Stevens E, Parker K, Abrams F. Mortality in elderly patients with heart failure. Cardiology Reviews 1999; 16: 40-5.
14. **Havranek EP** and Weinberger J. Update on the treatment of heart failure. Prog Cardiovasc Nursing 1999; 15: 111-3.
15. **Havranek EP**. Commentary on Rubins et al, “Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol”. ACP Journal Club 2000; 132: 44.
16. **Havranek EP**. Commentary on Pitt et al, “Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- the Losartan Heart Failure Survival Study ELITE II”. ACP Journal Club 2000; 133: 87.
17. **Havranek EP** (series editor). Improving heart failure care: HCFA’s initiative.
18. Ordin DL, Masoudi FA, Krumholz HM, **Havranek EP**. Medicare initiatives to improve heart failure care: An introduction. CHF 2000; 6: 280-2.
19. Masoudi FA, Ordin DL, Delaney RJ, Krumholz HM, **Havranek EP**. The National Heart Failure Project: A Health Care Financing Administration initiative to improve the care of Medicare beneficiaries with heart failure. CHF 2000; 6: 377-9.
20. Masoudi FA, Ralston DL, Wolfe P, **Havranek EP**, Shah VP, Krumholz HM, Ordin DL. Baseline quality indicator rates from the Nation Heart Failure Project: A HCFA initiative to improve the care of Medicare Beneficiaries with heart failure. CHF 2001; 7: 53-6.
21. Taylor J, Mulgrew C, Hayes R, Ordin DL, **Havranek EP**. Heart failure practice improvement effort in the outpatient setting: a Health Care Financing Administration initiative to improve the care of Medicare beneficiaries with heart failure. CHF 2001; 7: 105-8.
22. Delaney R, **Havranek EP**, Ordin DL, Taylor J. Profiles of quality improvement efforts in heart failure care. CHF 2001; 7: 166-9.
23. Miller GL, Mills MA, **Havranek EP**, Taylor JP, Ordin DL. Improving heart failure care in the office stetting CHF 2001; 7: 239-40.
24. **Havranek EP**, Masoudi FA, Smith G, Wolfe P, Ralston DL, Krumholz HM, Ordin DL. Lessons learned from the National Heart Failure project. CHF 2001; 7: 334-6.
25. Ramunno LD, French LL, Ligor ML, **Havranek EP**, Taylor JP, Ordin DL. Improving heart failure care in outpatient practices. CHF 2002; 8 : 86-89.
26. **Havranek EP**, Masoudi FA, Ralston DL, Krumholz HM, Taylor JP. Future challenges in quality improvement in heart failure. CHF, 8:342-5.
27. **Havranek EP**. Commentary on Pignone et al, “Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials” ACP Journal Club 2000; 134: 92.
28. **Havranek EP**. Editorial Comment- Catching the missed opportunities in heart failure. J Cardiac Failure 2001; 7: 239-40.
29. Masoudi FM and **Havranek EP**. Race and responsiveness to drugs for heart failure. N Engl J Med 2001; 345: 767.
30. **Havranek EP**. Book Review: Lactate Threshold Training. Am J Med Sports 2002; 4:407.
31. **Havranek EP**. Commentary on Page et al, “Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial” ACP Journal Club 2003; 138: 8.
32. **Havranek EP**. Book Review: Performing in Extreme Environments. Am J Med Sports 2003; 5:111.
33. **Havranek EP**. Commentary on Shepherd et al, “Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial” ACP Journal Club 2003; 139:9 and Evidence-based Medicine 2003; 8:107.
34. Foody JM, Ferdinand FD, Galusha D, Rathore SS, Masoudi FA, **Havranek EP**, Nilasena D, Radford MJ, Krumholz HM. Patterns of secondary prevention in older patients undergoing coronary artery bypass grafting during hospitalization for acute myocardial infarction. Circulation 2003; 108; II-24 – II-28.
35. **Havranek EP** and Masoudi FA. Editorial Comment - What we’re talking about when we talk about race. J Am Coll Cardiol 2004; 43: 436-7.
36. **Havranek EP**. Commentary on Mora et al, “Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the Lipid Research Clinics Prevalence Study” ACP Journal Club 2004; 140: 79.
37. **Havranek EP** and Steiner JF. Editorial- Valuation of health states in the US versus the UK: Two measures divided by a common language? Med Care 2005; 43: 201-2.
38. **Havranek EP**. Editorial Comment- Improving the outcomes of heart failure care: putting technology second. J Am Coll Cardiol 2005; 45:1665-6.
39. Nallamothu BK, **Havranek EP**, Masoudi FM, Cascells WS, Payvar S, Foody JM, Kosiborod MH, Wang Y, Krumholz HM. Research Correspondence- Admission body temperature and mortality in elderly patients hospitalized for heart failure. J Am Coll Cardiol 2006; 47: 2563-4.
40. **Havranek EP**. “Prevalence of depression in chronic heart failure”. in *Clinical Psychology and Heart Disease*. Molinari E, Compare A, Parati G, eds., Springer, Milan, 2006.
41. **Havranek EP**. Commentary on Brindle et al, “The accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review”. ACP Journal Club 2007; 146: 80. also Evidence-Based Medicine 2007; 12: 87.
42. **Havranek EP**. Editorial- Smoking cessation counseling and the quality of care for acute myocardial infarction. Am Heart J 2007; 154: 211-2.
43. **Havranek EP**. Commentary on Nordestgaard et al, “Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women”. ACP Journal Club 2008; 148: 23.
44. **Havranek EP**. Invited Commentary on Smith et al, “A randomized trial of direct-to-patient communication to enhance adherence to post-MI beta-blocker therapy”. Arch Int Med 2008; 168: 483.
45. Bekelman DB and **Havranek EP**. Palliative care for patients with acute decompensated heart failure: an underused service? Nat Clin Pract Cardiovasc Med 2008; 5: 250-1.
46. **Havranek EP**. Editorial Comment- From black and white to shades of gray: Race and RAS blockade. J Am Coll Cardiol 2008; 51:1872-3.
47. **Havranek EP** and Allen LA. Editorial Comment- Listening to patients. J Am Coll Cardiol 2008; 52: 1709-10.
48. State of Colorado Senate Bill 07-196 Health Information Technology Advisory Committee Report & Recommendations. April 2009. available at: http://www.colorado.gov/cs/Satellite?c=Page&childpagename=OIT-New/OITXLayout&cid=1165692953878&pagename=OITXWrapper&rendermode=live
49. **Havranek EP**. Editorial - Atrial fibrillation through the patient’s eyes. Circ Arrhythmia Electrophysiol 2009; 2: 213-214.
50. **Havranek EP** and Peterson PN. Editorial - Are implanted defibrillators effective therapy in the elderly? Asked, not answered. Circ Heart Failure 2010; 3:4-6.
51. **Havranek EP**. Chapter 38: Measuring Quality Outcomes in Heart Failure. in Mann DL. *Heart Failure. A Companion to Braunwald’s Heart Disease.* 2d ed. Elsevier Saunders, St. Louis (2011).
52. **Havranek EP**. Commentary on Nordmann et al, “Meta-analysis comparing Mediterranean to low-fat diets for modification of cardiovascular risk factors” ACP Journal Club 2011; 155:JC 6-3.
53. Blair IV, Steiner JF, **Havranek EP**. Unconscious (implicit) bias and health disparities: where do we go from here? The Permanente Journal 2011; 15: 71-78.
54. Hakim JG, Matenga JA, **Havranek EP**, Kao D. Health workforce development with a focus on CVD in Zimbabwe: The CHRIS Program, a Medical Education Partnership Initiative. Global Heart 2011; 6: 219-220
55. **Havranek EP**. Editorial Comment - Unseen consequences: The uninsured, doctors, and cardiovascular disease. J Am Coll Cardiol2013*;* 61: 1076-7. PMID: 23375928
56. **Havranek EP**. Editorial Comment - Capturing complexity: Socioeconomic disadvantage and heart failure outcomes. Circ Heart Fail 2015; 8: 413-414.
57. Perman SM, **Havranek EP**. Exploring providers' perspectives on early decisions to withdraw life-sustaining therapy after cardiac arrest. One side of the story. Ann Am Thorac Soc 2016; 13(7): 1008-9.
58. Ritchie ND, **Havranek EP**, Moore SL, Pereira RI. Proposed Medicare coverage for diabetes prevention: strengths, limitations, and recommendations for improvement. Am J Prev Med 2017; 53(2): 260-263. PMID: 28336351.
59. **Havranek EP** and Daugherty SL. Editorial - Talking with patients is better than talking to patients. Circ Cardiovac Qual Outcomes 2017;10(9). pii: e004041. PMID: 28830862
60. **Havranek EP.** Commentary - The influence of social and economic factors on heart disease. JAMA Cardiol [Epub ahead of print October 9, 2019]. PMID: 31596424

**BIBLIOGRAPHY- Abstracts**

1. Miller WP, **Havranek EP**, and Nellis SH. Calcium availability and history dependence of regional end-systolic relations. Circulation 1988; 78 Suppl II: II-248.
2. Veerakul G, **Havranek E**, Henry T, Beavers T, Bailey W, Read R, Harris M, Nademanee K. Intravascular ultrasound detection of aortic tear from chest trauma: diagnostic features and pitfalls, Circulation 1992; 86 Suppl I: I-845.
3. Reusch JJ, Wolfel EE, **Havranek EP**, Regensteiner JG, Savage S, Schrier RW. Cardiovascular exercise performance is reduced in non-insulin dependent diabetes mellitus, Annual Meeting of the Western Section, American Federation of Clinical Research, Carmel, CA, February 17-20, 1993.
4. Adair OV, Rainquet S, Pearson T, Mallet JM, **Havranek E**, Nadamanee K. Echocardiography abnormalities in chronic cocaine users, Annual Meeting of the Western Section, American Federation of Clinical Research, Carmel, CA, February 12, 1994.
5. **Havranek EP**, Harris ML, Nadamanee K. Chronic cocaine use impairs endothelium-dependent vasorelaxation, American College of Cardiology Annual Scientific Session, Atlanta, GA, March 13-17,1994. J Am Coll Cardiol 1994; 1A-274A.
6. Nadamanee K, Adair OV, **Havranek EP**, Pearson T, Bailey WM, DiPasquale J. A prospective study of cocaine related morbidity and mortality: chronic cocaine users versus postangioplasty patients, American College of Cardiology Annual Scientific Session, Atlanta, GA, March 13-17,1994; J Am Coll Cardiol 1994; 1A-337A.
7. Adair OV, Rainguet S, Pearson T, Mallet J, **Havranek E**, Nadamanee K. Echocardiographic abnormalities in chronic cocaine users, American College of Cardiology Annual Scientific Session, Atlanta, GA, March 13-17,1994; J Am Coll Cardiol 1994; 1A-150A.
8. Nadamanee K, Taylor RD, Bailey WM, Pearson TL, Adair OV, **Havranek EP**. Mechanisms of cocaine-induced sudden death and cardiac arrhythmias, American Heart Association Scientific Sessions, Dallas, TX, November 14-17, 1994. Circulation 1994 Suppl I; 90: I-455.
9. Graham GW, Pan Z, **Havranek EP**. Differences between cardiologists and primary care physicians in outpatient management of heart failure, American College of Cardiology Annual Scientific Session, Orlando, FL, March 27, 1996. J Am Coll Cardiol 1996; 1A-367A.
10. Estacio RO, **Havranek EP**, Jeffers BW, Krick D, Samsen O, Schrier RW. Deletion polymorphism of the angiotensin-converting enzyme (ACE) gene is associated with an increase in left ventricular mass in males with NIDDM. American Diabetes Association, Boston, MA, June 21-24, 1997.
11. **Havranek EP**, McGovern KM, Brocato AD, Lowes BD, Abraham WT. Utilities are valid measures of outcome in heart failure. Heart Failure Society of America, Baltimore, MD, September 21-24, 1997.
12. Abraham WT, Lowes BD, Roden RL, Gilbert EM, **Havranek EP**, White M, Zisman LS, Rose CP, Bristow MR. Tracer norepinephrine kinetics in the coronary circulation of patients with idiopathic dilated cardiomyopathy: evidence for decreased neuronal norepinephrine reuptake. Heart Failure Society of America, Baltimore, MD, September 21-24, 1997.
13. Abraham WT, Lowes BD, Roden RL, Gilbert EM, **Havranek EP**, White M, Zisman LS, Rose CP, Bristow MR. Mechanism of increased cardiac adrenergic activity in heart failure: evidence for decreased cardiac neuronal norepinephrine reuptake. American Heart Association Scientific Sessions, Orlando, FL, November 9-12, 1997. Circulation 1997; 96: I-92.
14. **Havranek EP**, Thomas I, Smith WB, Ponce G, Bilsker M, Munger M, Lyver S, Aarons D, Graves T, Wolf RA for the Irbesartan CHF Group. Dose-related beneficial long-term hemodynamic and clinical effects of irbesartan in heart failure. American Heart Association Scientific Sessions, Orlando, FL, November 9 -12, 1997. Circulation 1997; 96: I-452.
15. **Havranek EP**, Stevens E, Parker K, Abrams F. Determinants of mortality in elderly patients with heart failure: the role of angiotensin converting enzyme inhibitors. American Heart Association Scientific Sessions, Orlando, FL, November 9 -12, 1997. Circulation 1997; 96: I-617.
16. **Havranek EP**, Ware MG, Brocato AD, Lowes BD. The prevalence of depression in patients with heart failure. Heart Failure Society of America, Boca Raton, FL, September 14-16, 1998. J Cardiac Failure 1998; 4: I-53.
17. Lindenfeld JA, Abrams F, **Havranek EP**, Stevens B. Heart failure is due to diastolic dysfunction in women more often than in men. Heart Failure Society of America, Boca Raton, FL, September 14-16, 1998. J Cardiac Failure 1998; 4: I-52.
18. **Havranek EP** and Weinberger J. Concomitant use of ACE inhibitors and antiplatelet therapy therapies: clopidogrel versus aspirin. European Society of Hypertension, Milan, June 12, 1999.
19. **Havranek EP**, Ralston D, Delaney RE, Westfall K, Wolfe P, Debuhr J, Mulgrew C, Krumholz HM, Masoudi FA, Ordin DL. Current rates of ACE inhibitor use in Medicare beneficiaries with heart failure. Heart Failure Society of America, Boca Raton, FL, September 10-13, 2000. J Cardiac Failure 2000; 6(Suppl 2): 83.
20. Ordin DL, Masoudi FA, **Havranek EP**, Debuhr J, Mulgrew C, Krumholz, HM. Design of the National Heart Failure Project: a Health Care Financing Administration (HCFA) initiative to improve heart failure care. Heart Failure Society of America, Boca Raton, FL, September 10-13, 2000. J Cardiac Failure 2000; 6(Suppl 2): 85.
21. Ordin DL, Westfall K, Wolfe P, Krumholz HM, Masoudi FA, Debuhr J, Mulgrew C, Ralston D, **Havranek EP**. Current rates of ACE inhibitor use in Medicare beneficiaries with heart failure: Results from the National Heart Failure project. American Heart Association Scientific Sessions, New Orleans, LA, November 12-15, 2000. Circulation 2000; II-593.
22. Masoudi FA, **Havranek EP**, Krumholz HM, Westfall K, Wolfe P, Ordin DL. Current national rates of ACE inhibitor dosing for Medicare beneficiaries with heart failure: Results from the National Heart Failure project. American College of Cardiology Annual Scientific Session, Orlando, FL, March 18-21, 2001. J Am Coll Cardiol 2001;
23. **Havranek EP**, Masoudi FA, Wolfe P, Westfall K, Delaney R, Mulgrew C, Krumholz HM, Ordin DL. Eligibility for new therapies in elderly heart failure patients: Results from the National Heart Failure project. American College of Cardiology Annual Scientific Session, Orlando, FL, March 21, 2001. J Am Coll Cardiol 2001;
24. Gottlieb S, Brater DC, Thomas I, **Havranek E**, Bourge R, Golman S, Dyer F, Gomez M, Beckman E, Abraham W. BG9719 (CVT-124), an A1-adenosine receptor antagonist, protects against the decline in renal function observed with standard congestive heart failure therapy. American College of Cardiology Annual Scientific Session, Orlando, FL, March 21, 2001. J Am Coll Cardiol 2001;
25. Smith GL, **Havranek EP**, Masoudi FA, Wolfe P, Ordin DL, Krumholz HM. Sex and heart failure with preserved systolic function. Heart Failure Society of America 5th Annual Scientific Meeting, Washington DC, September 10-11, 2001. J Cardiac Failure 2001; 7: II-68.
26. **Havranek EP**, Wolfe P, Masoudi FA, Krumholz HM, Ordin DL. Explaining geographic variation in the care of elderly heart failure patients. Heart Failure Society of America 5th Annual Scientific Meeting, Washington DC, September 10-11, 2001. J Cardiac Failure 2001; 7: II-75.
27. Smith GL, **Havranek EP**, Masoudi FA, Wolfe P, Ordin DL, Krumholz HM. Sex differences in quality of care for patients with heart failure. Heart Failure Society of America 5th Annual Scientific Meeting, Washington DC, September 10-11, 2001. J Cardiac Failure 2001; 7: II-76.
28. **Havranek EP**, Wolfe P, Masoudi FA, Krumholz HM, Rathore SS, Stevens B, Ordin DL. Regional differences in quality of care for heart failure: the role of patient, physician, and hospital characteristics. American College of Cardiology Annual Scientific Sessions, Atlanta, GA, March17-20, 2002. J Am Coll Cardiol 2002; 39: 452A.
29. Foody JM, Rathore SS, Wang Y, Masoudi FA, **Havranek EP**, Ordin DL, Krumholz HM. Physician specialty and quality of care for elderly patients hospitalized with heart failure. American College of Cardiology Annual Scientific Sessions, Atlanta, GA, March 17-20, 2002. J Am Coll Cardiol 2002; 39: 458A.
30. Spertus JA, Conard MW, Rinaldi J, Tsuyuki, Krumholz H, Pina I, **Havranek E**, Tooley JF, for the Cardiovascular Outcomes Research Consortium (CORC). The Kansas City Cardiomyopathy Questionnaire is sensitive to clinical change in congestive heart failure. American College of Cardiology Annual Scientific Sessions, Atlanta, GA, March 17-20, 2002. J Am Coll Cardiol 2002; 39: 460A.
31. Masoudi FA, Smith GL, **Havranek EP**, Fish RH, Wolfe P, Stevens BR, Ordin DL, Krumholz HM, Foody JM. Gender is more important than advancing age as a predictor of preserved systolic function in older persons hospitalized with heart failure. American College of Cardiology Annual Scientific Sessions, Atlanta, GA, March17-20, 2002. J Am Coll Cardiol 2002; 39: 461A.
32. **Havranek EP**, Masoudi FA, Rumsfeld JS, Spertus JA, Tooley JF for the Cardiovascular Outcomes Research Consortium (CORC). Depression in heart failure patients is not the result of comorbidities or medications. Heart Failure Society of America 6th Annual Scientific Meeting, Boca Raton, FL, September 23, 2002. J Cardiac Failure 2002; 8: S70.
33. Rumsfeld JS, **Havranek EP**, Masoudi FA, Krumholz HM, Spertus JA for the Cardiovascular Outcomes Research Consortium (CORC). Depressive symptoms are the strongest correlate of quality of life in patients with heart failure. Heart Failure Society of America 6th Annual Scientific Meeting, Boca Raton, FL, September 23, 2002, J Cardiac Failure 2002; 8: S14, and American Heart Association Scientific Sessions, Chicago, IL, November 17-20, 2002, Circulation 2002; 106: II-472.
34. **Havranek E**, Simon T, L'Italien G, Smitten A, Hauber AB, Chen R, Lapuerta P. The relationship between health perception and utility in heart failure patient in a clinical trial: results from the OVERTURE study. American Heart Association 4th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, October 13, 2002. Circulation 2002; 106(16): e76-e123.
35. Foody JM, Rathore SS, Galusha DH, Masoudi FA, **Havranek EP**, Radford MJ, Ordin DL, Krumholz HM. National patterns of care for patients with non ST-elevation MI: Insights from the National AMI project. American Heart Association 4th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, October 13, 2002 Circulation 2002; 106(16): e76-e123.
36. **Havranek EP**, Wolfe P, Stevens BR, Radford MJ, Rathore SS, Ordin DL, Masoudi FA. Nursing home patients hospitalized with heart failure are undertreated: results from the National Heart Failure Project. American Heart Association 4th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, October 13, 2002 Circulation 2002; 106(16): e76-e123, and American Heart Association Scientific Sessions, Chicago, IL, November 17-20, 2002, Circulation 2002; 106: II-512.
37. Rathore SS, **Havranek EP**, Foody JM, Radford MJ, Ordin DL, Masoudi FA, Krumholz HM. Race, sex, and the treatment of elderly patients hospitalized with heart failure. American Heart Association 4th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, October 13, 2002. Circulation 2002; 106(16): e76-e123, and American Heart Association Scientific Sessions, Chicago, IL, November 17, 2002, Circulation 2002; 106: II-681.
38. Masoudi FA, Rumsfeld JS, **Havranek EP**, Krumholz HM, Spertus JA for the Cardiovascular Outcomes Research Consortium (CORC). Age, quality of life, and functional limitation in heart failure. American Heart Association 4th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, October 13, 2002 Circulation 2002; 106(16): e76-e123, and American Heart Association Scientific Sessions, Chicago, IL, November 17, 2002, Circulation 2002; 106: II-757.
39. Foody JM, Rathore SS, **Havranek EP**, Radford MJ, Ordin DL, Masoudi FA, Krumholz HM. Trends in AMI care: the National AMI Project 1998 to 2002. American Heart Association 4th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, October 13, 2002 Circulation 2002; 106(16): e76-e123, and American Heart Association Scientific Sessions, Chicago, IL, November 17, 2002, Circulation 2002; 106: II-722.
40. Foody JM, Rathore SS, **Havranek EP**, Radford MJ, Ordin DL, Masoudi FA, Krumholz HM. Older patients undergoing CABG less likely to receive evidence-based therapies at discharge: insights from the National AMI Project. American Heart Association Scientific Sessions, Chicago, IL, November 17, 2002, Circulation 2002; 106: II-604.
41. Masoudi FA, Wolfe P, Rathore SS, Foody JM, Ordin DL, Krumholz HM, **Havranek EP**. Left ventricular systolic function and survival in a contemporary cohort of patients with heart failure. American College of Cardiology Scientific Sessions, Chicago, IL, March 30-April 3, 2003, J Am Coll Cardiol 2003; 41: 147A.
42. Foody JM, Rathore SS, Wang YF, Herrin J, Masoudi FA, **Havranek EP**, Radford MJ, Ordin DL, Krumholz HM. Physician specialty and survival following hospitalization for heart failure. American College of Cardiology Scientific Sessions, Chicago, IL, March 30-April 3, 2003, J Am Coll Cardiol 2003; 41: 189A.
43. Rathore SS, Foody JM, Wang YF, Smith GL, Herrin J, Masoudi FA, Ordin DL, **Havranek EP**, Krumholz HM. Racial differences in mortality among elderly patients hospitalized with heart failure. American College of Cardiology Scientific Sessions, Chicago, IL, March 30-April 3, 2003, J Am Coll Cardiol 2003; 41: 189A.
44. Masoudi FA, Stevens BR, Foody JM, **Havranek EP**, Krumholz HM, Ordin DL. National trends in the care of patients with heart failure, 1998-2001: Results from the CMS National Heart Failure project. American College of Cardiology Scientific Sessions, Chicago, IL, March 30-April 3, 2003, J Am Coll Cardiol 2003; 41: 518A.
45. Steinberg J, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell WB, **Havranek E**, Murray K, Olshansky B, O’Neil G, Sami M, Schmidt S, Storm R, Zabalgoita M, Miller J. Comparison of modes of death between randomized treatment strategies in the AFFIRM study. North American Society of Pacing and Electrophysiology Scientific Sessions, Washington, DC May 1-17, 2003.
46. Rathore SS, Masoudi FA, Wang YF, Foody JM, **Havranek EP**, Krumholz HM. Patient characteristics associated with underuse of ACE inhibitors among elderly Medicare beneficiaries hospitalized for heart failure. Heart Failure Society of America 7th Annual Scientific Meeting, Las Vegas, September 23, 2003. J Cardiac Failure 2003; 9: S85.
47. Masoudi FA, Rathore SS, Wang YF, **Havranek EP**, Foody JM, Krumholz HM. The effectiveness of ACE inhibitors in Medicare beneficiaries with heart failure and left ventricular systolic dysfunction: results from the National Heart Care Project. Heart Failure Society of America 7th Annual Scientific Meeting, Las Vegas, September 23, 2003. J Cardiac Failure 2003; 9: S86.
48. Greenberg BH, Banish D, Goldman S, Thomas I, **Havranek E**, Bijou R, O’Leary M, Zhu Y, Ticho B, Massie B, Abraham W. BG9928, an oral adenosine antagonist, preserves renal function, improves sodium excretion and is well tolerated in heart failure patients. American Heart Association Scientific Sessions, Orlando, FL, November 9-12, 2003, Circulation 2003; 108: IV-342.
49. Rathore SS, Masoudi FA, Wang Y, Foody JM, **Havranek EP**, Krumholz HM. Socioeconomic status and the treatment of elderly patients hospitalized with heart failure. American Heart Association Scientific Sessions, Orlando, FL, November 9-12, 2003, Circulation 2003; 108: IV-344.
50. Masoudi FA, Rathore SS, Wang Y, **Havranek EP**, Foody JM, Krumholz HM. National patterns of use and effectiveness of ACE inhibitors in older patients with heart failure and left ventricular systolic dysfunction. American Heart Association Scientific Sessions, Orlando, FL, November 9-12, 2003, Circulation 2003; 108: IV-486.
51. Kosiborod M, Curtis JP, Smith GL, Masoudi FA, **Havranek EP**, Krumholz HM. Anemia is not an independent predictor of mortality in patients with heart failure- results from the National Heart Failure Project. American Heart Association Scientific Sessions, Orlando, FL, November 9-12, 2003, Circulation 2003; 108: IV-665.
52. **Havranek EP**, Masoudi FA, Rumsfeld JS, Luther SA, McCullough PA, Jones PG, Rathore SS. Changes in BNP level are not associated with outcomes in outpatients with heart failure. American Heart Association Scientific Sessions, Orlando, FL, November 9-12, 2003, Circulation 2003; 108: IV-692.
53. Heidenreich PA, Jones PG, Rumsfeld JS, Masoudi FA, **Havranek EP**, Conard M, Weintraub WS, Williams RE. The prognostic value of the Kansas City Cardiomyopathy Questionnaire. American Heart Association Scientific Sessions, Orlando, FL, November 9-12, 2003, Circulation 2003; 108: IV-715.
54. Foody JM, Galusha DH, Rathore SS, Masoudi FA, **Havranek EP**, Krumholz HM. Trends in non-ST-segment elevation myocardial infarction care: The National Acute Myocardial Infarction Project 1998-2001. American College of Cardiology Scientific Sessions, New Orleans, LA, March 7-March 10, 2004, J Am Coll Cardiol 2004; 43: 263A.
55. Kosiborod M, Rathore SS, Wang Y, Inzucchi SE, Masoudi FA, **Havranek EP**, Foody JM, Krumholz HM. Prognostic implications of admission hyperglycemia in elderly patients with acute myocardial infarction. American College of Cardiology Scientific Sessions, New Orleans, LA, March 7-March 10, 2004, J Am Coll Cardiol 2004; 43: 241A.
56. Rathore SS, Masoudi FA, Wang Y, Foody JM, Curtis JP, **Havranek EP**, Krumholz HM. Socioeconomic status and outcomes of elderly patients hospitalized with heart failure. American College of Cardiology Scientific Sessions, New Orleans, LA, March 7-March 10, 2004, J Am Coll Cardiol 2004; 43: 414A.
57. Masoudi FA, Gross CP, Wang Y, Rathore SS, **Havranek EP**, Foody JM, Krumholz HM. National patterns of spironolactone prescription for older patients with heart failure and left ventricular systolic dysfunction before and after RALES. American College of Cardiology Scientific Sessions, New Orleans, LA, March 7-March 10, 2004, J Am Coll Cardiol 2004; 43: 415A.
58. Foody JM, Galusha DH, Masoudi FA, Rathore SS, **Havranek EP**, Krumholz HM. Trends in use of statins in older patients with heart failure. American College of Cardiology Scientific Sessions, New Orleans, LA, March 7-March 10, 2004, J Am Coll Cardiol 2004; 43: 446A.
59. Foody JM, Galusha DH, Masoudi FA, Rathore SS, **Havranek EP**, Krumholz HM. Trends in use of statins in older patients with acute myocardial infarction. American College of Cardiology Scientific Sessions, New Orleans, LA, March 7-March 10, 2004, J Am Coll Cardiol 2004; 43: 481A.
60. Luther SA, McCullough PA, Rumsfeld JS, Jones PG, Peterson ED, Rathore SS, **Havranek EP**, Spertus JA, Masoudi FA. B-type natriuretic peptide levels are not associated with health status in patients with heart failure. American Heart Association 5th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, May 16-17, 2004. Circulation 2004; 109(20): e231-e284.
61. Morgan A, Masoudi FA, **Havranek EP**, Jones PG, Peterson PN, Spertus JA, Rumsfeld JS. Difficulty with medication adherence is associated with worse health status in heart failure patients. American Heart Association 5th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, May 16-17, 2004. Circulation 2004; 109(20): e231-e284.
62. **Havranek EP**, Spertus JA, Masoudi FA, Jones PG, Rumsfeld JS. Predictors of the onset of depressive symptoms in heart failure patients. American Heart Association Scientific Sessions, New Orleans, LA, November 7-10, 2004, Circulation 2004; 110: III-477.
63. Masoudi FA, Baillie C, Wang Y, **Havranek EP**, Foody JM, Krumholz HM. The burden of polypharmacy in older persons hospitalized with heart failure. American Heart Association Scientific Sessions, New Orleans, LA, November 7-10, 2004, Circulation 2004; 110: III-817.
64. Rathore SS, Curtis JP, Foody JM, Wang YF, Kosiborod M, McNamara RL, Masoudi FA, **Havranek EP**, Krumholz HM. Association of primary percutaneous coronary intervention door-to-balloon time and mortality in elderly patients hospitalized with ST-elevation myocardial infarction. American College of Cardiology Scientific Sessions, Orlando, FL, March 6-9, 2005, J Am Coll Cardiol 2005; 45: 80A.
65. Eng MH, Rumsfeld, **Havranek EP**, Jones PG, Magid DJ, Messenger JC, Spertus JA, Rathore SS, Krumholz HM, Masoudi FA. Use of the early invasive strategy in older patients with acute coronary syndromes: insights from the PREMIER registry. American College of Cardiology Scientific Sessions, Orlando, FL, March 6-9, 2005, J Am Coll Cardiol 2005; 45: 190A.
66. Eng MH, Rumsfeld, **Havranek EP**, Jones PG, Magid DJ, Messenger JC, Spertus JA, Rathore SS, Krumholz HM, Masoudi FA. Contemporary patterns of use of evidence-based medical therapy in older patients with myocardial infarction: Results of the PREMIER registry. American College of Cardiology Scientific Sessions, Orlando, FL, March 6-9, 2005, J Am Coll Cardiol 2005; 45: 342A.
67. **Havranek EP**, Wolfe P, Masoudi FA, Foody JM, Rathore SS, Krumholz HM. The relationship between quality of care and reimbursement for patients hospitalized with heart failure. American College of Cardiology Scientific Sessions, Orlando, FL, March 6-9, 2005, J Am Coll Cardiol 2005; 45: 339A.
68. Amin AA, **Havranek EP**, Jones AM, Mallik S, Masoudi FA, Nugent K, Rumsfeld JS, Vaccarino V, Woodman C, Krumholz HM, Spertus JA. Predictors of persistent depression 1 month after myocardial infarction. American Heart Association 6th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, May 15-16, 2005. Circulation 2005; 111(20): e310-e359.
69. Amin AA, **Havranek EP**, Jones AM, Mallik S, Masoudi FA, Nugent K, Rumsfeld JS, Vaccarino V, Woodman C, Krumholz HM, Spertus JA. Predictors of moderate/severe depressive symptoms 1 month after myocardial infarction. American Heart Association 6th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, May 15-16, 2005. Circulation 2005; 111(20): e310-e359.
70. Plomondon ME, Magid DJ, Masoudi FA, Jones PG, Barry LC, **Havranek EP**, Peterson ED, Krumholz HM, Spertus JA, Rumsfeld JS. The impact of angina on patient satisfaction after acute myocardial infarction. American Heart Association Scientific Sessions, Dallas, TX, November 13-16, 2005, Circulation 2005; 112: II-823.
71. Abdalla M, Gulanski B, Wang Y, **Havranek EP**, Masoudi FA, Krumhholz HM, Foody JM. Ten-year mortality for older diabetics hospitalized with acute myocardial infarction. American Heart Association Scientific Sessions, Dallas, TX, November 13-16, 2005, Circulation 2005; 112: II-788.
72. Krantz MJ, **Havranek EP**, Haynes D, Smith I, Bartelson BB, Long CS. Inpatient beta-blocker initiation with nurse-management improves outcome in vulnerable patients with heart failure. American Heart Association Scientific Sessions, Dallas, TX, November 13-16, 2005, Circulation 2005; 112: II-796.
73. Ho PM, Rumsfeld JS, Curtis JP, Eng MH, **Havranek EP**, Jones PG, Krumholz HM, Magid DJ, Messenger JC, Peterson ED, Rathore SS, Spertus JA, Masoudi FA. Age and health status following non-ST elevation myocardial infarction. American Heart Association Scientific Sessions, Dallas, TX, November 13-16, 2005, Circulation 2005; 112: II-807.
74. Riegel B, Moser DK, Powell M, Rector T, **Havranek EP**. Non-pharmacological management practices among heart failure experts. American Heart Association Scientific Sessions, Dallas, TX, November 13-16, 2005, Circulation 2005; 112: II-528.
75. **Havranek EP**, Masoudi FA, Krantz MJ, Hanratty RL, Estacio RO, Bublitz C, Steiner JF. Which ECG criteria for left ventricular hypertrophy best predict mortality? American College of Cardiology Scientific Sessions, Atlanta, GA, March 11-13, 2006, J Am Coll Cardiol 2006; 47: 13A.
76. Luther SA, Ho PM, Spertus JA, Jones PG, Rumsfeld JS, Krumholz HM, Weintraub WS, **Havranek EP**, Bach RG, Peterson ED, Masoudi FA. Early follow-up after AMI is associated with higher rates of cardioprotective medication use. American Heart Association 7th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, May 7-9, 2006. Circulation 2006; 113(21): e820.
77. Buchanan DM, Jones PG, Rumsfeld JS, Amin AA, Ho PM, Masoudi FA, **Havranek EP**, Mallik S; Spertus JA. Trajectories of depression severity following acute myocardial infarction: a latent-class analysis. American Heart Association 7th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, May 7-9, 2006. Circulation 2006; 113(21): e798.
78. Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, **Havranek EP**, Krumholz HM. Discontinuation of antihyperglycemic therapy and mortality after acute myocardial infarction. American Diabetes Association 2006 Scientific Sessions; June 9-13, 2006; Washington, DC.
79. Rumsfeld JS, Masoudi FA, Jones PG, **Havranek EP**, Peterson ED, Krumholz HM, Spertus JA. Predictors of 1-year quality of life after acute myocardial infarction. American Heart Association Scientific Sessions, Chicago, IL, November 12-15, 2006, Circulation 2006; 114: II-842.
80. Padilla R, Fernald D, **Havranek E**, MacKenzie TD, Steiner JF. Designing a hypertension control outreach program: Qualitative community feedback. Society of General Internal Medicine 30th Annual Meeting, Toronto, Ontario, April 25-28, 2007. J Gen Int Med 2007; 22 (Suppl 1): 113.
81. Bekelman D, Rumsfeld J, **Havranek E**, Yamashita T, Kutner J. Symptoms, depression, and spiritual well-being: A comparison of heart failure and advanced cancer patients. Society of General Internal Medicine 31st Annual Meeting, Pittsburgh, PA April 9-12, 2008, J Gen Int Med 2008; 23 (Suppl 2): 406. and American Heart Association 9th Scientific Forum on Quality of Care and Outcomes Research, Baltimore, MD, April 30- May 2, 2008. Circulation 2008; 117(21): e447.
82. Shetterly SM, Tavel H, Ho PM, Crounse L, Maddox TM, **Havranek EP**, Daugherty SL, Rumsfeld JS, Magid DJ. Assessing potential inclusion criteria for a hypertension disease registry using administrative clinical databases. American Heart Association 9th Scientific Forum on Quality of Care and Outcomes Research, Baltimore, MD, April 30- May 2, 2008. Circulation 2008; 117(21): e464.
83. Kosiborod M, Inzucchi S, Spertus JA, Wang Y, Masoudi FA, **Havranek EP**, Krumholz HM. Elevated glucose and mortality in patients hospitalized with heart failure. American Heart Association Scientific Sessions, New Orleans, LA, November 10-12, 2008. Circulation 2008; 118: S1117.
84. Fitzgerald AA, Peterson PN, Magid DJ, Masoudi FA, Allen L, Clarke C, Ho M, Shetterly S, Powers D, **Havranek EP**. Adherence to evidence-based pharmacotherapy reduces the risk of death and rehospitalization in patients with heart failure. American College of Cardiology Scientific Sessions, Orlando, FL, March 28-31, 2009. J Am Coll Cardiol 2009; 53: A378.
85. Magid DJ, Ho M, Welch L, Olson K, Snow K, Lambert-Kerzner A, Brand D, Plomondon M, **Havranek E**. An interactive voice recognition response technology-based intervention to improve blood pressure control. American Heart Association 10th Scientific Forum on Quality of Care and Outcomes Research, Washington, DC, April 23-25, 2009. Circ CV Quality Outcomes 2009; 2: e55.
86. Krantz MJ, Long CS, Benton K, Karamkhani E, Dickinson LM, Estacio RO, Masoudi FA, **Havranek EP**. Pulse wave velocity predicts pre-clinical atherosclerosis among Latino patients with chronic hypertension. American Society of Hypertension 24th Annual Scientific Meeting, San Francisco, CA, May 6-9, 2009. Journal of Clinical Hypertension 2009; 11(S1): A98.
87. Long CS, Krantz MJ, Estacio RO, Masoudi FA, Coyle D, Neuman C, Smith I, Karamkhani E, **Havranek EP**. LpPLA2, not hsCRP, provides improved risk discrimination among a cohort of hypertensive Latinos in a safety-net institution. American Society of Hypertension 24th Annual Scientific Meeting, San Francisco, CA, May 6-9, 2009. Journal of Clinical Hypertension 2009; 11(S1): A65.
88. Hanratty R, Chonchol M, Dickinson LM, Beaty BL, Estacio RO, MacKenzie T, Hurley LP, Linas SL, Steiner JF, **Havranek EP**. Kidney function decline and incident chronic kidney disease in individuals with hypertension by race and ethnicity. Society of General Internal Medicine 32d Annual Meeting, Miami, FL, May 13-16, 2009. J Gen Int Med 2009; 24 Suppl 1; S113.
89. Wang CCL, Pereira RI, Benton K, Dickinson M, Estacio R, Krantz M, Neuman C, Long C, **Havranek E**, Chonchol M. Association between 25-hydroxyvitamin D levels and insulin resistance in hypertensive subjects. 14th Workshop on Vitamin D abstract book 2009.
90. Hanratty H, Chonchol MB, Powers JD, Dickinson LM, Tavel H, Beaty B, Chan PS, **Havranek EP**, SteinerJF. Comparison of estimated glomerular filtration rates using the chronic kidney disease Epidemiology Collaboration Equation versus the Modification of Diet in Renal Disease equation in hypertensive subjects. American Society of Nephrology Annual Meeting. San Diego, CA, October 31, 2009. available at http://www.abstracts2view.com/asn/view.php?nu=ASN09L1\_4159a
91. Wang CCL, Pereira RI, Benton KL, Dickinson LM, Estacio RO, Mori J. Krantz MJ, Neuman C, Long CS, **Havranek E**, Chonchol MB. Vitamin D levels and insulin resistance in a mostly Latino hypertensive cohort. American Society of Nephrology Annual Meeting. San Diego, CA, October 31, 2009. available at: http://www.abstracts2view.com/asn/view.php?nu=ASN09L1\_163a
92. **Havranek EP**, Gosch KL, Smolderen KG, Buchanan DM, Spertus JA. Social network characteristics are associated with long term outcomes after myocardial infarction. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington, DC, May 19-21, 2010.
93. Lambert-Kerzner A, **Havranek EP**, Plomondon ME, Albright K, Moore A, Gryniewicz K, Magid D, Ho PM. Patient’s perspectives on a multifaceted intervention with a focus on technology: A qualitative analysis. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington, DC, May 19-21, 2010.
94. Blair I, Price D, **Havranek E**, Steiner J, Hanratty R, Fairclough D, Farley T, Katz H. Implicit and explicit ethnic/racial attitudes among primary care providers and community members. 17th Annual HMO Research Network Conference, March 23-25, 2011, Boston, Massachusetts. Clin Med Research 2011; 3/4: 165.
95. Hanratty R, Blair I, Steiner J, Dickinson LM, Tate C, Cohen G, **Havranek E.** The effect of a self-affirmation writing exercise on race-discordant patient-provider communication. Society for General Internal Medicine 35th Annual Meeting, Orlando, FL, May 9-12, 2012.
96. Martin SS, Joshi PH, Blaha MJ, Kulkarni KKR, Khokhar A, Maddox TM, **Havranek EP**, Toth PP, Li Y, Spertus JA, Jones SR. Remnant lipoprotein cholesterol and mortality after acute myocardial infarction: The TRIUMPH Prospective Multi-Center Registry. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2013 Scientific Sessions, Baltimore, MD, May 15-17, 2013. Circ Cardiovasc Qual Outcomes. 2013;6:3 Supplement A60
97. Lambert-Kerzner A, **Havranek** EP, Plomondon ME, Albright K, Blatchford P, Fagan K, McCreight M, Ho PM. Patients' perspectives of participating in an intervention to improve medication adherence after ACS hospitalization: A qualitative analysis. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2013 Scientific Sessions, Baltimore, MD, May 15-17, 2013. Circ Cardiovasc Qual Outcomes. 2013;6:3 Supplement A129
98. Burke JM, Weeks WB, Westrich JL, Savitz LA, Dunlay SM, Wennberg DE, **Havranek** EP. The relationship between readmission cost and total cost over time for heart failure. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2013 Scientific Sessions, Baltimore, MD, May 15-17, 2013. Circ Cardiovasc Qual Outcomes. 2013;6:3 Supplement A157
99. Trent SA, Quinlan M, Susalla M, Johnson MA, Byyny RL, Sankoff J,Havranek EP, Haukoos JS. Adherence and health disparities associated with common clinical practice guidelines in the emergency department. Society of Academic Emergency Medicine Annual Meeting, Dallas, TX, May 13-17, 2014. Acad Emergency Med 2014; 21 Suppl s1: s136.
100. Daugherty SL, **Havranek EP**, Blair IV, Dickinson M, Bronsert M, Karimkhani E, Main D, Masoudi FA. Differences in cardiologists’ interpretation and management of chest pain symptoms and abnormal stress tests in women and men. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2014 Scientific Sessions, Baltimore, MD, June 2-5, 2014. Circ Cardiovasc Qual Outcomes. 2014;7(Suppl 1):3 Supplement
101. Daugherty SL, Blair IV, **Havranek EP**, Main D, Dickinson M, Bronsert M, Karimkhani E, Masoudi FA. Gender bias among cardiology physicians. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2014 Scientific Sessions, Baltimore, MD, June 2-5, 2014. Circ Cardiovasc Qual Outcomes. 2014;7(Suppl 1):3 Supplement
102. Fischer IP, Fischer HH, Pereira RI, Rozwadowski JM, Gutierrez-Ragunath S, Furniss AL, Durfee MJ, Moore SL, Tsai AG, Albright K, **Havranek EP**. Text messaging versus usual care for weight loss in patients with pre-diabetes. Society of General Internal Medicine 38th Annual Meeting, Toronto, ON, Canada, April 22-25, 2015. J Gen Int Med 2015; 30(2) Suppl: S265.
103. Oronce CI, Beck AL, Goodrich GK, Durfee MJ, Madrid S, Dircksen S, Moore SL, Davidson A, Steiner JF, **Havranek EP**. Using electronic health systems to investigate the geographic variation in depression prevalence across Denver, Colorado. Society of General Internal Medicine 38th Annual Meeting, Toronto, ON, Canada, April 22-25, 2015. J Gen Int Med 2015; 30(2) Suppl: S295.
104. Thompson LE, Furniss A, Masoudi FA, Peterson PN Main D, Dickinson LM, Karimkhani EK, Blair IV, **Havranek EP**, Daugherty SL. Variation in the use of angiography between procedural and non-procedural cardiologists. American Heart Association Scientific Sessions, Orlando, FL, November 8-11, 2015.
105. Vogel J, Ginde A, Fairclough D, **Havranek E**. A comparison of visit frequency and payer type at a large integrated, urban safety-net institution before and after the Affordable Care Act. Academy Health Annual Research Meeting, Boston, MA, June 26-28, 2016.
106. Vogel J, Jones J, Rising K, Ginde A, **Havranek E**. Reasons patients choose the emergency department over primary care: A qualitative metasynthesis. Academy Health Annual Research Meeting, Boston, MA, June 26-28, 2016.
107. Rinehart D, Leslie SE, Doyle R, Durfee J, Kuka K, Thomas-Gale T, Shlay J, **Havranek E**. Acceptability of a sexual health text messaging intervention to support young females in primary care. Academy Health Annual Research Meeting, Boston, MA, June 26-28, 2016.
108. Rowan SE , Joshua Durfee J, Tabano DC, Dircksen S, **Havranek E**, Truesdale A, Davidson A .The association between HCV and comorbid conditions in two large patient cohorts. 2017 Conference on Retroviruses and Opportunistic Infections (CROI), February 13 - 16, 2017, Seattle, Washington.
109. Rooks RN, DeYoung K, Shekiro E, **Havranek E**, Davidson A. Community environment associated with cardiovascular disease hospitalization rates in Denver,Colorado. American Heart Association EPI/LIFESTYLE 2017 Scientific Sessions, March 7 – 10, 2017, Portland, OR. Available at: <http://professional.heart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_492225.pdf>
110. **Havranek EP**, Moore SL, Dircksen S**. Creating an infrastructure to support patient engagement: Denver Health and Hospital Authority.**American Public Health Association 2017 Annual Meeting , Atlanta. November 4-8, 2017.
111. Rooks RN, **Havranek EP**, Fox E, Robinson J. Perceived neighborhood environment and left atrial measures in the Jackson Heart Study. Gerontological Society of America 2018 Annual Scientific Meeting, Boston, MA, November 14-18, 2018.
112. Mansoori J, Linde-Zwirble W, Hou PC, **Havranek E**, Douglas I. A retrospective analysis of under or over-resuscitation and risk-adjusted hospital mortality among mechanically ventilated patients with septic shock. American Thoracic Society International Conference, Dallas, TX, May 17-22, 2019.